Nicholas Haft
Founder at Delix Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Susan Graf | F | 52 | 3 years | |
| Chris Shumway | M | 58 | 4 years | |
| David E. Olson | M | - |
Delix Therapeutics, Inc.
 Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | - |
| Mark Rus | M | - |
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 3 years |
| Nick Haft | M | - |
Arcos Ventures SPV LLC
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 10 years |
| Lance Thibault | M | 58 | 1 years | |
| Paul Conley | M | 56 |
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 6 years |
| Vasudev Bailey | M | - |
Delix Therapeutics, Inc.
Delix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Delix Therapeutics, Inc. is a clinical-stage neuroscience company that focuses on developing novel neuroplasticity-promoting therapeutics to treat neuropsychiatric and neurological disorders. The company's compounds are small molecules that can induce structural and functional neural changes in targeted areas of the brain. Delix is pioneering a new class of fast-acting outpatient pharmacotherapies and advancing through preclinical and clinical development to bring patients FDA-approved, take-home medicines that will serve several unmet needs. The company is headquartered in Palo Alto, CA, and has subsidiaries in the United States. Delix was founded by David E. Olson, Nick Haft, Nicholas Haft, and Paul A. Conley, and Mark Rus has been the CEO of the company since 2021. | 3 years |
| Matthew Nelson | M | - | 3 years | |
| Matthew Blischak | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marc Blaustein | M | 61 | 2 years | |
| Mark Smith | M | 37 | 6 years | |
| Andrew Noh | M | - | 4 years | |
| Gregory Perry | M | 63 | 4 years | |
| Joseph Vittiglio | M | 52 | 2 years | |
| Samuel Hamood | M | 56 | - | |
| Zain Kassam | M | 42 | 4 years | |
| Anne Marie Conway | F | - | - | |
| Alka Batycky | M | 54 | 1 years | |
| Debra Silberg | M | - | - | |
| Chris Weidenmaier | M | - | - | |
| David Rhodes | M | - | 3 years | |
| David Pugatch | M | - | 2 years | |
| Bryan Gillis | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 24 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Nicholas Haft
- Personal Network
